Literature DB >> 17720520

Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).

Joachim H Ix1, Michael G Shlipak, Ronit Katz, Matthew J Budoff, David M Shavelle, Jeffrey L Probstfield, Junichiro Takasu, Robert Detrano, Kevin D O'Brien.   

Abstract

BACKGROUND: Aortic valve calcification (AVC) and mitral annular calcification (MAC) are highly prevalent and predictive of mortality in end-stage renal disease populations. Whether less severe kidney dysfunction is associated with AVC and MAC is uncertain. STUDY
DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: Ethnically diverse middle-aged adults without clinically apparent cardiovascular disease who participated in the Multi-Ethnic Study of Atherosclerosis. PREDICTOR: Estimated glomerular filtration rate (eGFR), cystatin C, and microalbuminuria. OUTCOMES & MEASUREMENTS: AVC and MAC were determined by means of computed tomography. Multivariable logistic regression evaluated the association of kidney function with AVC and MAC.
RESULTS: Of 6,785 participants, 10% had an eGFR less than 60 mL/min/1.73 m(2) (<1.0 mL/s/1.73 m(2)), mean cystatin C level was 0.9 +/- 0.2 mg/L, 7% had microalbuminuria (albumin >or= 30 mg/g), 15% had diabetes, 13% had AVC, and 9% had MAC. In adjusted analyses for AVC, eGFR less than 60 mL/min/1.73 m(2) (adjusted odds ratio, 1.23; 95% confidence interval, 0.99 to 1.14) and greater cystatin C concentrations (per SD increase; adjusted odds ratio, 1.06; 95% confidence interval, 0.99 to 1.14) had modest associations. Microalbuminuria was not associated independently with AVC (adjusted odds ratio, 1.11; 95% confidence interval, 0.89 to 1.40). For the MAC end point, associations of eGFR less than 60 mL/min/1.73 m(2) and greater cystatin C level differed by diabetes status (P for interaction = 0.1 and 0.02, respectively). In persons with diabetes, eGFR less than 60 mL/min/1.73 m(2) (adjusted odds ratio, 2.03; 95% confidence interval, 1.26 to 3.25) and greater cystatin C level (adjusted odds ratio, 1.38; 95% confidence interval, 1.14 to 1.68) were associated strongly, whereas no association was observed in subjects without diabetes (eGFR < 60 mL/min/1.73 m(2): adjusted odds ratio, 1.13; 95% confidence interval, 0.86 to 1.49; cystatin C: adjusted odds ratio, 1.03; 95% confidence interval, 0.93 to 1.13). The association of microalbuminuria with MAC (adjusted odds ratio, 1.37; 95% confidence interval, 1.06 to 1.76) did not differ by diabetes status (P for interaction = 0.2). LIMITATIONS: There were few participants with severe kidney disease.
CONCLUSIONS: Impaired kidney function had only a modest association with AVC, whereas its association with MAC was observed only in persons with diabetes. Future studies should evaluate whether associations of kidney impairment with dystrophic calcification differ by diabetes status in other clinical settings and vascular beds.

Entities:  

Mesh:

Year:  2007        PMID: 17720520     DOI: 10.1053/j.ajkd.2007.05.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  34 in total

Review 1.  The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.

Authors:  Sammy Elmariah; Emile R Mohler
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

2.  Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation.

Authors:  Ken Kitamura; Hideki Fujii; Kentaro Nakai; Keiji Kono; Shunsuke Goto; Tatsuya Nishii; Atsushi Kono; Shinichi Nishi
Journal:  Heart Vessels       Date:  2017-03-21       Impact factor: 2.037

3.  Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study.

Authors:  Jason P Linefsky; Kevin D O'Brien; Ronit Katz; Ian H de Boer; Eddy Barasch; Nancy S Jenny; David S Siscovick; Bryan Kestenbaum
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

4.  Mitral annular calcification in patients undergoing aortic valve replacement for aortic valve stenosis.

Authors:  Yoshiyuki Takami; Kazuyoshi Tajima
Journal:  Heart Vessels       Date:  2014-09-25       Impact factor: 2.037

Review 5.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

6.  Assessment of risk factors for developing incident aortic stenosis: the Tromsø Study.

Authors:  Gry Wisthus Eveborn; Henrik Schirmer; Per Lunde; Geir Heggelund; John-Bjarne Hansen; Knut Rasmussen
Journal:  Eur J Epidemiol       Date:  2014-07-15       Impact factor: 8.082

7.  Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults.

Authors:  Anna E Bortnick; Traci M Bartz; Joachim H Ix; Michel Chonchol; Alexander Reiner; Mary Cushman; David Owens; Eddy Barasch; David S Siscovick; John S Gottdiener; Jorge R Kizer
Journal:  Heart       Date:  2016-07-13       Impact factor: 5.994

8.  Cardiac valve calcification is associated with presence and severity of coronary artery disease in patients with pre-dialysis chronic kidney disease.

Authors:  Il Young Kim; Min Jung Kim; Dong Won Lee; Soo Bong Lee; Min Ji Shin; Harin Rhee; Byeong Yun Yang; Sang Heon Song; Eun Young Seong; Ihm Soo Kwak
Journal:  Clin Exp Nephrol       Date:  2015-03-12       Impact factor: 2.801

9.  Aortic valve calcification in mild primary hyperparathyroidism.

Authors:  Shinichi Iwata; Marcella Donovan Walker; Marco R Di Tullio; Eiichi Hyodo; Zhezhen Jin; Rui Liu; Ralph L Sacco; Shunichi Homma; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2011-10-26       Impact factor: 5.958

10.  Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Anh L Bui; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Linda F Fried; Joseph F Polak; Bruce A Wasserman; Mark J Sarnak; David Siscovick; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2008-09-27       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.